Science

Drew Moghanaki: Why there is a desire to deliver SBRT to ultra-central tumors

Andres Huertas, Drew Moghanaki and Shankar Siva

Feb 28, 2025, 14:43

Drew Moghanaki: Why there is a desire to deliver SBRT to ultra-central tumors

Drew Moghanaki, Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology at UCLA, shared an article by Andres Huertas, et al. on X:

“A trio of radiation oncologists from France, the United States, and Australia asks why there is a desire to deliver SBRT to ultra-central tumors.

Especially when a 3-week hypofractionation (60/15) course seems to be just fine.”

Comment on Wu et al’s article on toxicity in patients receiving radiotherapy for ultracentral stage I non-small cell lung cancer.

Authors: Andres Huertas, et al.

Drew Moghanaki: Why there is a desire to deliver SBRT to ultra-central tumors

Andres Huertas cancer Drew Moghanaki fight against cancer Global fight against cancer non small cell lung cancer NSCLC OncoDaily Oncology radiotherapy RadOnc SBRT UCLA ultra-central tumors

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

Highlights from ELCC 2025

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer

Meet the New AACR Board of Directores for 2025-2028 Term

Do Artificial Sweeteners Cause Cancer? Myths and Facts